XML 33 R20.htm IDEA: XBRL DOCUMENT v3.23.1
Segments
 3 Months Ended
Apr. 01, 2023
Segment Reporting [Abstract]  
Segments SegmentsThe Company’s two reportable segments are U.S. and International. The Company’s products are primarily sold to orthopedists, musculoskeletal and sports medicine physicians, podiatrists, neurosurgeons and orthopedic spine surgeons, as well as to their patients. The Company does not disclose segment information by asset as the Chief Operating Decision Maker does not review or use it to allocate resources or to assess the operating results and financial performance. Segment adjusted EBITDA is the segment profitability metric reported to the Company’s Chief Operating Decision Maker for purposes of decisions about allocation of resources to, and assessing performance of, each reportable segment.
The following table presents segment adjusted EBITDA reconciled to loss before income taxes:
Three Months Ended
April 1, 2023April 2, 2022
Segment adjusted EBITDA
U.S.$14,712 $4,839 
International2,239 2,333 
Interest (expense) income, net(9,694)1,550 
Depreciation and amortization(16,473)(12,479)
Acquisition and related costs(1,175)(7,978)
Restructuring and succession charges(317)(577)
Equity compensation(1,846)(4,889)
CartiHeal divestiture and debt restructuring(5,330)— 
Impairment of assets(78,615)— 
Other items(3,665)(2,336)
Loss before income taxes$(100,164)$(19,537)